Entheseal Doppler signals in ultrasound are associated with vasodilator drugs and age in patients with radiographic axial spondyloarthritis

Further Publications Rheumatology

Association of validated patient reported outcome measures with patients' self-reported disease status in axial spondyloarthritis

Rheumatology (Oxford)

Redeker I, Tsiami S, Klavdianou K, Oezdemir YE, Sewerin P, Kiefer D, Andreica I, Kernder A, Vossen D, Kiltz U, Baraliakos X

doi: 10.1093/rheumatology/keae648

Psoriatic Arthritis

Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study

Arthritis Res Ther

Currado D, Saracino F, Ruscitti P, Marino A, Pantano I, Vomero M, Berardicurti O, Pavlych V, Di Vico C, Caso F, Costa L, Tasso M, Camarda F, Misceo F, De Vincenzo F, Corrado A, Arcarese L, Rigon A, Vadacca M, Corberi E, Kun L, Trunfio F, Pilato A, Lamberti L, Cantatore FP, Perosa F, Guggino G, Scarpa R, Cipriani P, Ciccia F, Giacomelli R, Navarini L

doi: 10.1186/s13075-024-03396-5

Psoriatic Arthritis

Access, Effectiveness, Safety And Survival Of Secukinumab In Patients With Axial Spondyloarthritis And Axial Psoriatic Arthritis: Real-Life Study In Argentina

J Rheumatol

Martire MV, Marin J, Maldonado Ficco H, Benegas M, Giorgis P, Vila D, Isnardi CA, Gamba MJ, Flores Trejo JF, Perez-Alamino R, Chemez AJ, Ferreyra Garrott L, Cosatti MA, Buschiazzo EA, Correa MLA, Aguila Maldonado R, Manases Roldan B, Lizarraga C, Alfaro MA, Morbiducci J, Ingolotti LV, Pendón G, Nieto RE, Velloso MS, Martinez Muñoz A, Lloves Schenone N, Zamora NV, Saturansky E, Costi AC, Haye Salinas MJ, Airoldi CA, Granel A

doi: 10.3899/jrheum.2024-1185

Further Publications Rheumatology

Biologic disease-modifying antirheumatic drugs survival in late-onset axial spondyloarthritis-data from a Portuguese registry

Rheumatology (Oxford)

Silva SP, Monteiro B, Pinto Oliveira C, Pereira da Costa R, Matos CO, Lopes MD, Gomes CM, Bernardes M, Santos ME, Gago L, Abreu C, Fraga V, Mendes B, Lucas Rocha M, Soares CD, Silva C, Santos H, Valente P, Silva L, Eugénio G, Barcelos A

doi: 10.1093/rheumatology/keaf176

Further Publications ImmunologyFurther Publications Rheumatology

Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration

Adv Ther

Navarro-Compán V, Reveille JD, Rahman P, Maldonado-Cocco JA, Magrey M, Bolce R, Panni T, Kronbergs A, Rudwaleit M

doi: 10.1007/s12325-025-03305-5

Further Publications Rheumatology

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study

Arthritis Res Ther

Van den Bosch F, Deodhar A, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Baraliakos X, Bu X, Lagunes-Galindo I, Song IH, Wung P, Kato K, Shmagel A

doi: 10.1186/s13075-024-03441-3

Further Publications Rheumatology

Improvement in spinal pain at night and its impact on long-term outcomes in radiographic axial spondyloarthritis: Results from Ixekizumab COAST-V randomised trial

Semin Arthritis Rheum

Ramiro S, Lukas C, Nissen MJ, Zhu B, Ng KJ, Sheesh M, Doridot G, Liu-Leage S, Chan A, Fang Y, Wei JC

doi: 10.1016/j.semarthrit.2024.152571

Further Publications Rheumatology

Disease characteristics, co-morbidities and treatment response in a contemporary axial spondyloarthritis cohort: Analysis of 717 patients from the Greek AxSpA registry

Semin Arthritis Rheum

Papagoras C, Fragoulis GE, Fytanidis N, Krikelis M, Mole E, Gazi S, Skepastianos V, Kougkas N, Dimitroulas T, Koletsos N, Kaltsonoudis E, Voulgari PV, Karamanakos A, Pappa M, Tektonidou MG, Sfikakis PP, Klavdianou K, Kalavri E, Kottas K, Katsifis G, Konsta M, Grika EP, Sfontouris C, Mavrea E, Koutsianas C, Kataxaki E, Sampatakaki E, Zoupidou K, Katsimpri P, Iliopoulos A, Iliopoulos G, Daoussis D, Bournazos I, Karokis D, Patrikos D, Vassilopoulos D

doi: 10.1016/j.semarthrit.2025.152645

Further Publications Rheumatology

Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From the Randomized, Placebo-Controlled, Phase III INVIGORATE-1 Study

Arthritis Rheumatol

Deodhar A, Supronik J, Kivitz A, Valenzuela G, Kapur K, Rohrer S, Dokoupilova E, Richards HB, Pavelka K

doi: 10.1002/art.42993

Related content

Association of validated patient reported outcome measures with patients' self-reported disease status in axial spondyloarthritis

Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study

Access, Effectiveness, Safety And Survival Of Secukinumab In Patients With Axial Spondyloarthritis And Axial Psoriatic Arthritis: Real-Life Study In Argentina

Biologic disease-modifying antirheumatic drugs survival in late-onset axial spondyloarthritis-data from a Portuguese registry

Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study

Improvement in spinal pain at night and its impact on long-term outcomes in radiographic axial spondyloarthritis: Results from Ixekizumab COAST-V randomised trial

Disease characteristics, co-morbidities and treatment response in a contemporary axial spondyloarthritis cohort: Analysis of 717 patients from the Greek AxSpA registry

Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From the Randomized, Placebo-Controlled, Phase III INVIGORATE-1 Study